Details of the Drug
General Information of Drug (ID: DMX1POR)
| Drug Name |
MYOSEVERIN
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
myoseverin; 267402-71-1; 9-Isopropyl-N2,N6-bis-(4-methoxybenzyl)-9H-purine-2,6-diamine; 9-Isopropyl-N2,N6-bis(4-methoxybenzyl)-9H-purine-2,6-diamine; AC1L1HSM; AC1Q4VJQ; 9-Isopropyl-2,6-bis(4-methoxybenzylamino)purine; CHEMBL141689; SCHEMBL13325947; CTK8E8888; MolPort-003-958-703; HMS2043N15; KS-000012SJ; ZINC2583630; n,n'-bis(4-methoxybenzyl)-9-(propan-2-yl)-9h-purine-2,6-diamine; HSCI1_000041; IN1218; AKOS027326433; TRA0035814; SMP2_000092; NCGC00165829-01; ACM267402711; RT-013973; M2373; J-016534
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 432.5 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 4.3 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 9 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 7 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||


